Erasca Announces FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme and Collaboration with GCAR for Potential Inclusion in GBM AGILE Clinical Trial
December 17, 2021 08:00 ET
|
Erasca, Inc.
IND filing achieved ahead of schedule; dosing of first patient in THUNDERBBOLT-1 Phase 1 clinical trial in recurrent GBM anticipated in Q1 2022 Early collaboration with GCAR could support potential...
Erasca Added to the Nasdaq Biotechnology Index
December 14, 2021 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference
November 16, 2021 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Reports Third Quarter 2021 Financial Results and Business Updates
November 10, 2021 16:05 ET
|
Erasca, Inc.
Strong execution leading to four ongoing clinical trials evaluating lead candidates ERAS-007 (ERKi) and ERAS-601 (SHP2i) Named one of Fierce Biotech’s “Fierce 15” most promising biotechnology...
Erasca Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EGFR Inhibitor with Broad Activity against Oncogenic EGFR Alterations, at AACR Conference on Brain Cancer
October 25, 2021 16:01 ET
|
Erasca, Inc.
ERAS-801's CNS penetration: four times higher than approved EGFR inhibitorsComprehensive inhibition against oncogenic EGFR vIII and wildtype alterationsImproved outcomes in over 90% of EGFR-driven...
Erasca is Named One of Fierce Biotech’s “Fierce 15” Biotechnology Companies of 2021
September 27, 2021 08:01 ET
|
Erasca, Inc.
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
Erasca Announces First Patient Dosed in HERKULES-3, a Phase 1b/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations
September 22, 2021 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations
September 09, 2021 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Encorafenib Combination
September 08, 2021 08:00 ET
|
Erasca, Inc.
ERAS-007, a potential best-in-class ERK1/2 inhibitor, will be evaluated in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) HERKULES-3...
Erasca to Participate in the Morgan Stanley 19th Annual Global Healthcare Virtual Conference
September 02, 2021 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...